Citigroup Upgrades Tandem Diabetes Care (NASDAQ:TNDM) to Buy

Citigroup upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM – Free Report) from a neutral rating to a buy rating in a research report released on Wednesday morning, Marketbeat reports. Citigroup currently has $57.00 price target on the medical device company’s stock, up from their previous price target of $40.00. Several other analysts have also recently […]

Related Keywords

United States ,Stifel Nicolaus ,Robertw Baird ,Pricet Rowe Associates Inc ,Silvercrest Asset Management Group ,Bellevue Group ,Wells Fargo Company ,Barclays ,Citigroup ,Tandem Diabetes Care Inc ,First Light Asset Management ,Tandem Diabetes Care ,Free Report ,Moderate Buy ,Diabetes Care ,Get Free Report ,Asset Management Group ,Light Asset Management ,Pricet Rowe Associates ,Tandem Mobi ,Tandem Diabetes Care Daily ,